Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding - 2The Difficulties of Getting a Green Card in the US
- 3Sydney Sweeney's American Eagle campaign and Kendrick Lamar's Super Bowl performance were among the 10 biggest pop-culture moments of 2025
- 4Whale stranded off Germany for days found stuck again
- 5Vote In favor of Your Favored Shades
- The Manual for Decent European Urban communities in 2024
- Collierville residents with no power as temperatures plunge
- Death toll from floods in Afghanistan rises to 61
- Step by step instructions to Pick an Incineration Urn: Variables to Consider
- Genesis Marks 10th Anniversary With Magma GT Concept Aimed at High-Performance Flagships
- Winter storm warnings issued across Northeast as up to 9 inches of snow forecast; deadly atmospheric river in California snarls travel
- Fascinating Fishing Objections From Around The World
- Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- Terminal cancer diagnosis announced by JFK's granddaughter
